CN Mobile Logo

Search form


Breast Cancer Gene Patent Resolved

Breast Cancer Gene Patent Resolved

WASHINGTON--The National Institutes of Health, University of Utah, and Myriad Genetics, Inc. have resolved issues involving patenting of the BRCA1 breast cancer gene by agreeing that scientists from all three institutions should be named as joint inventors in current patent applications. The agreement also ensures that exclusive, worldwide commercial rights are retained by Myriad and its licensees, Eli Lilly and Company and Hybritech Incorporated.

By clicking Accept, you agree to become a member of the UBM Medica Community.